Zenas BioPharma (NASDAQ:ZBIO), trading on NASDAQ under the ticker ZBIO, is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics targeting metabolic, degenerative and immuno-oncology indications. Founded in Europe in 2016, the company has established its corporate headquarters in Cambridge, Massachusetts, with additional research operations in Tübingen, Germany. Zenas BioPharma’s scientific platform centers on small-molecule inhibitors that modulate key enzymatic pathways implicated in chronic disease, including 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and other targets involved in tissue remodeling and inflammation.
At the core of Zenas BioPharma’s pipeline is a lead candidate designed to address nonalcoholic steatohepatitis (NASH) by selectively inhibiting 11β-HSD1 in the liver and adipose tissue, with the goal of reducing fibrosis and improving metabolic health. Preclinical studies have demonstrated favorable pharmacokinetic and safety profiles, enabling the program’s advancement toward early-stage clinical trials. In parallel, the company is advancing a portfolio of immuno-oncology and degenerative disease assets, leveraging proprietary chemistry and in vitro screening platforms to identify first-in-class or best-in-class molecules with differentiated mechanisms of action.
Zenas BioPharma serves a global market, engaging with strategic partners and contract research organizations across North America and Europe to accelerate development timelines and optimize resource allocation. The company’s leadership team combines seasoned industry veterans and academic experts, led by CEO Dr. Andrew Mangan, who brings more than two decades of biopharmaceutical and investment experience. Dr. Emily Chen, Chief Scientific Officer, oversees translational research efforts, while a board of directors with deep expertise in clinical development, regulatory affairs and commercial strategy guides corporate governance and long-term planning.
With a commitment to innovation and collaboration, Zenas BioPharma aims to address unmet medical needs by translating cutting-edge science into therapeutics that improve patient outcomes. As the company prepares for upcoming clinical milestones, it continues to expand its research capabilities, strengthen intellectual property, and explore strategic alliances to support the advancement of its novel small-molecule pipeline.
